Division of Infectious Diseases, Department of Medicine, Stanford University, 300 Pasteur Drive, Grant S-146, Stanford, CA 94305, USA.
J Antimicrob Chemother. 2010 Jul;65(7):1477-85. doi: 10.1093/jac/dkq140. Epub 2010 May 12.
We characterized pairwise and higher order patterns of non-nucleoside reverse transcriptase inhibitor (NNRTI)-selected mutations because multiple mutations are usually required for clinically significant resistance to second-generation NNRTIs.
We analysed viruses from 13 039 individuals with sequences containing at least one of 52 published NNRTI-selected mutations, including 1133 viruses from individuals who received efavirenz but no other NNRTI and 1510 viruses from individuals who received nevirapine but no other NNRTI. Of the 17 reported etravirine resistance-associated mutations (RAMs), Y181C/I/V, L100I, K101P and M230L were considered major based on published in vitro susceptibility data.
Efavirenz preferentially selected for 16 mutations, including L100I (14% versus 0.1%, P < 0.001), K101P (3.3% versus 0.4%, P < 0.001) and M230L (2.8% versus 1.3%, P = 0.004), whereas nevirapine preferentially selected for 12 mutations, including Y181C/I/V (48% versus 6.9%, P < 0.001). Twenty-nine pairs of NNRTI-selected mutations covaried significantly, including Y181C with seven other mutations (A98G, K101E/H, V108I, G190A/S and H221Y), L100I with K103N, and K101P with K103S. Two pairs (Y181C + V179F and Y181C + G190S) were predicted to confer >10-fold decreased etravirine susceptibility. Seventeen percent of sequences had three or more NNRTI-selected mutations, mostly in clusters of covarying mutations. Many clusters had Y181C plus a non-major etravirine RAM; few had more than one major etravirine RAM.
Although major etravirine RAMs rarely occur in combination, 2 of 29 pairs of covarying mutations were associated with >10-fold decreased etravirine susceptibility. Viruses with three or more NNRTI-selected mutations often contained Y181C in combination with one or more minor etravirine RAMs; however, phenotypic and clinical correlates for most of these higher order combinations have not been published.
我们对非核苷类逆转录酶抑制剂(NNRTI)选择的突变进行了两两和更高阶的模式分析,因为对于第二代 NNRTI 临床上显著的耐药性通常需要多种突变。
我们分析了来自 13039 名个体的病毒序列,这些序列包含至少 52 种已发表的 NNRTI 选择突变中的一种,包括 1133 种来自接受依非韦伦但未接受其他 NNRTI 的个体的病毒和 1510 种来自接受奈韦拉平但未接受其他 NNRTI 的个体的病毒。在 17 种报告的依曲韦林耐药相关突变(RAM)中,Y181C/I/V、L100I、K101P 和 M230L 根据已发表的体外药敏数据被认为是主要突变。
依非韦伦优先选择了 16 种突变,包括 L100I(14%对 0.1%,P < 0.001)、K101P(3.3%对 0.4%,P < 0.001)和 M230L(2.8%对 1.3%,P = 0.004),而奈韦拉平优先选择了 12 种突变,包括 Y181C/I/V(48%对 6.9%,P < 0.001)。29 对 NNRTI 选择的突变显著共变,包括 Y181C 与其他 7 种突变(A98G、K101E/H、V108I、G190A/S 和 H221Y)、L100I 与 K103N 和 K101P 与 K103S。两对(Y181C + V179F 和 Y181C + G190S)被预测为埃替拉韦敏感性降低 10 倍以上。17%的序列有三种或三种以上的 NNRTI 选择突变,主要是在共变突变的簇中。许多簇中都有 Y181C 加上一种非主要的埃替拉韦 RAM;很少有超过一种主要的埃替拉韦 RAM。
尽管主要的埃替拉韦 RAM 很少组合出现,但 29 对共变突变中的 2 对与埃替拉韦敏感性降低 10 倍以上有关。三种或三种以上 NNRTI 选择突变的病毒通常含有 Y181C 与一种或多种次要的埃替拉韦 RAM 组合;然而,这些高阶组合的表型和临床相关性大多数尚未发表。